Methods for medicinal dosage determination and diagnosis

• US 8,463,552 B1
• Filed: 10/18/2006
• Issued: 06/11/2013
• Est. Priority Date: 10/18/2005
• Status: Active Grant

• Current Assignee: Jonathan M. Koller, Kevin J. Black
• Original Assignee: Jonathan M. Koller, Kevin J. Black
• Inventors: Black, Kevin J., Koller, Jonathan M.
• Primary Examiner(s): Clow, Lori A
• Application Number:
  US11/583,896
• Time in Patent Office: 2,428 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: G01R 33/4806 Functional imaging of brain activation
• CPC Class Codes: G16C 20/30 Prediction of properties of chemical compounds, compositions or mixtures
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 30/20 for handling medical images, e.g. DICOM, HL7 or PACS
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

The present invention is directed to systems and methods for diagnosing tissue abnormality or diseases, determining effective drug dosages, and monitoring therapeutic drug treatments. The methods and systems described utilize tissue imaging in situ and computer modeling.

Claims

1. A method for determining quantitative pharmacodynamic parameters for a pharmacologically active agent in a biological organism, the method comprising:

a) administering to a biological organism a plurality of doses of the pharmacologically active agent, over a sufficiently brief time interval, wherein the response of the biological organism to the pharmacologically active agent does not return to baseline between doses;

b) collecting biological imaging data comprising the biological organism'"'"'s response to the plurality of doses of the pharmacologically active agent administered in a), in a single imaging session, over the sufficiently brief time interval; and

c) fitting predetermined pharmacokinetic-pharmacodynamic models to said imaging data to determine the quantitative pharmacodynamic parameters for said pharmacologically active agent comprising;

i) setting up fit parameters and choosing a fit method;

ii) computing best-fit parameters and their goodness of fit to the biological data using the selected fit method;

iii) computing the statistical significance of the best-fit parameters; and

iv) generating an output.

2. The method of claim 1 wherein the imaging data is collected on a magnetic resonance imaging device.

3. The method of claim 1, wherein the imaging data is collected on a magnetic resonance imaging device sensitive to a blood oxygen level dependent signal.

4. The method of claim 1 wherein the imaging data is collected using Positron Emission Tomography.

5. The method of claim 1 wherein the imaging data is collected on a Single Photon Emission Computed Tomography imaging device.

6. The method of claim 1 wherein the pharmacologically active agent is a medicament and the organism is a human.

7. The method of claim 1 wherein the quantitative pharmacodynamic parameters are selected from the group consisting of E_max, Hill coefficient, EC_K, ED₅₀, k_e0, and t_1/2eq.

8. The method of claim 1 wherein the imaging method does not provide stable quantitative measures.

9. The method of claim 8 wherein the non-stable quantitative measurements are used without modification in fitting predetermined pharmacokinetic pharmacodynamic models.

12. The method of claim 6 wherein the imaging data is collected on a magnetic resonance imaging device sensitive to blood oxygen level dependent signal.

13. The method of claim 6 wherein the imaging data is collected using Positron Emission Tomography.

14. The method of claim 6 wherein the imaging data is collected on a Single Photon Emission Computed Tomography imaging device.

15. The method of claim 6 wherein the pharmacologically active agent is a medicament and the organism is a human.

16. The method of claim 6 wherein the quantitative pharmacodynamic parameters are selected from the group consisting of E_max, Hill coefficient, EC₅₀, ED₅₀, k_e0, and t_1/2eq.

17. The method of claim 6 wherein the non-stable quantitative measurements are used without modification in fitting predetermined pharmacokinetic pharmacodynamic models.

10. A method for quantitatively characterizing an organ'"'"'s response to a pharmaceutically active agent, comprising:

a) administering to a biological organism a plurality of doses of a pharmacologically active agent, over a sufficiently brief time interval, wherein the response of the biological organism to the pharmacologically active agent does not return to baseline between doses,

b) collecting non-stable quantitative biological imaging data comprising a response of the organ to the plurality of doses of the pharmacologically active agent administered in a), in a single imaging session, over the sufficiently brief time interval and,

determining quantitative pharmacodynamics parameters for the pharmacologically active agent by fitting predetermined pharmacokinetic-pharmacodynamic models to the nonquantitative biological imaging data comprising;

i) setting up fit parameters and choosing a fit method;

ii) computing best-fit parameters and their goodness of fit to the biological data using the selected fit method;

iii) computing the statistical significance of the best-fit parameters; and

iv) generating an output.

11. The method of claim 10 wherein the imaging data is collected on a magnetic resonance imaging device.